within Pharmacolibrary.Drugs.ATC.A;

model A10AE05
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 4.6666666666666666e-07,
    adminDuration  = 600,
    adminMass      = 0.4 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 7.000000000000001e-05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A10AE05</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Insulin detemir is a long-acting human insulin analogue used for the treatment of diabetes mellitus in adults, adolescents, and children aged 1 year and above. It provides basal insulin coverage to help control blood glucose levels and is approved for use in most countries worldwide.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy subjects and patients with type 1 diabetes; parameters predominantly from subcutaneous administration in adult males and females.</p><h4>References</h4><ol><li><p>Mathiesen, ER, et al., &amp; Damm, P (2023). Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open‑label, multinational, randomised, controlled, non-inferiority trial. <i>The lancet. Diabetes &amp; endocrinology</i> 11(2) 86–95. DOI:<a href=\"https://doi.org/10.1016/S2213-8587(22)00307-2\">10.1016/S2213-8587(22)00307-2</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36623517/\">https://pubmed.ncbi.nlm.nih.gov/36623517</a></p></li><li><p>Russell-Jones, D, &amp; Khan, R (2007). Insulin-associated weight gain in diabetes--causes, effects and coping strategies. <i>Diabetes, obesity &amp; metabolism</i> 9(6) 799–812. DOI:<a href=\"https://doi.org/10.1111/j.1463-1326.2006.00686.x\">10.1111/j.1463-1326.2006.00686.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17924864/\">https://pubmed.ncbi.nlm.nih.gov/17924864</a></p></li><li><p>Pedersen, KM, et al., &amp; Refsgaard, HHF (2022). Optimization of pig models for translation of subcutaneous pharmacokinetics of therapeutic proteins: Liraglutide, insulin aspart and insulin detemir. <i>Translational research : the journal of laboratory and clinical medicine</i> 239 71–84. DOI:<a href=\"https://doi.org/10.1016/j.trsl.2021.08.005\">10.1016/j.trsl.2021.08.005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34428585/\">https://pubmed.ncbi.nlm.nih.gov/34428585</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A10AE05;
